Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042366 · ClinicalTrials.gov registry record · Phase 2
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
A Phase 2 study, sponsored by John Kirkwood.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01042366 is a Phase 2 study that was terminated before completion, run by John Kirkwood. The registered enrollment target is 16 participants.
The verdict
NCT01042366, a Phase 2 study, was terminated before completion, sponsored by John Kirkwood.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what effect using an experimental tumor vaccine (a substance or group of substances meant to cause the immune system to respond to a tumor) made using patients' own tumor cells and blood cells will have on their melanoma.
Interventions
- BIOLOGICAL Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2002-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042366
The ClinicalTrials.gov registry entry for NCT01042366 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Kirkwood, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vaccination is the first listed.
NCT01042366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042366 about?
NCT01042366 is a clinical study titled "Dendritic Cells (DC) Vaccine for Metastatic Melanoma". The purpose of this study is to determine what effect using an experimental tumor vaccine (a substance or group of substances meant to cause the immune system to respond to a tumor) made using patients' own tumor cells and blood cells will have on their melanoma.
What is the current status of trial NCT01042366?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2002-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01042366?
The interventions under investigation include: Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT01042366?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.